SG11201606275WA - Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders - Google Patents

Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Info

Publication number
SG11201606275WA
SG11201606275WA SG11201606275WA SG11201606275WA SG11201606275WA SG 11201606275W A SG11201606275W A SG 11201606275WA SG 11201606275W A SG11201606275W A SG 11201606275WA SG 11201606275W A SG11201606275W A SG 11201606275WA SG 11201606275W A SG11201606275W A SG 11201606275WA
Authority
SG
Singapore
Prior art keywords
acamprosate
baclofen
treatment
combination
medium chain
Prior art date
Application number
SG11201606275WA
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Rodolphe Hajj
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of SG11201606275WA publication Critical patent/SG11201606275WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201606275WA 2014-02-11 2015-02-10 Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders SG11201606275WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938340P 2014-02-11 2014-02-11
PCT/EP2015/052694 WO2015121218A1 (en) 2014-02-11 2015-02-10 Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
SG11201606275WA true SG11201606275WA (en) 2016-08-30

Family

ID=52544464

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606275WA SG11201606275WA (en) 2014-02-11 2015-02-10 Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Country Status (12)

Country Link
US (1) US10905672B2 (ja)
EP (1) EP3104850A1 (ja)
JP (1) JP6619744B2 (ja)
KR (1) KR20160111013A (ja)
CN (1) CN106456583B (ja)
AU (1) AU2015217796B2 (ja)
CA (1) CA2938361A1 (ja)
EA (1) EA201691602A1 (ja)
IL (1) IL246856A0 (ja)
MX (1) MX2016010409A (ja)
SG (1) SG11201606275WA (ja)
WO (1) WO2015121218A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160111013A (ko) 2014-02-11 2016-09-23 파넥스트 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합
AU2016258624B2 (en) 2015-05-04 2021-07-29 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
BR112019019098A2 (pt) 2017-03-15 2020-04-22 Cerecin Inc composições farmacêuticas tendo altos carregamentos de fármaco de triglicerídeos de cadeia média, seu método de produção e seu uso
KR20200005576A (ko) 2017-05-17 2020-01-15 컨플루언스 파마슈티컬스, 엘엘씨 호모타우린 및 이의 염의 제형
CN111902138A (zh) * 2018-01-29 2020-11-06 法奈克斯公司 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗
CN112566629B (zh) * 2018-03-15 2023-11-17 睿升公司 具有高药物装载的中链甘油三酯的药物组合物及其相关方法
CN111166868A (zh) * 2019-07-17 2020-05-19 江苏西宏生物医药有限公司 一种用于治疗神经疾病和障碍的组合物
KR20210072569A (ko) * 2019-12-09 2021-06-17 주식회사 종근당 도네페질 및 메만틴을 포함하는 복합 제제
JP2023525712A (ja) * 2020-05-19 2023-06-19 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 認知機能を改善するためのmct製剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323940T3 (es) * 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7109239B2 (en) 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US7227028B2 (en) 2003-12-30 2007-06-05 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US20080206332A1 (en) 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090069419A1 (en) 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
CL2008002960A1 (es) * 2007-10-04 2009-05-08 Bio Arch Lab Inc Método para producir 2-ceto-3-desoxi d-gluconato (kdg), basado en proporciopnar acido-desoxi l-eritro hexocelulosa uronico (dehu), y contactar dicha molecula con un microorganismo recombinante que codofica una dehu-hidrogenasa.
US20090099253A1 (en) 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
TW200936123A (en) 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
JP5721230B2 (ja) 2008-04-29 2015-05-20 ファーネクストPharnext 血管新生の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ
EP3560496A1 (en) 2008-04-29 2019-10-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
MX2010011880A (es) 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
NZ594648A (en) 2009-03-03 2013-12-20 Xenoport Inc Sustained release oral dosage forms of an r-baclofen prodrug
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9494605B2 (en) 2009-11-20 2016-11-15 Pharnext Diagnostic tools for charcot-marie-tooth disease
AU2010336921A1 (en) 2009-12-30 2012-07-26 Baylor Research Institute Anaplerotic therapy for Alzheimer's disease and the aging brain
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
WO2012117075A2 (en) 2011-03-01 2012-09-07 Pharnext Treatment of cerebral ischemia
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
AU2013291970B2 (en) 2012-07-18 2017-09-28 Pharnext Baclofen and acamprosate based therapy of Macular Degeneration disorders
EP2705841A1 (en) 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
EP2705843A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
EP2727587A1 (en) 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EA029478B1 (ru) 2013-06-05 2018-03-30 Фарнекст Стабильные растворы объединенных активных фармацевтических ингредиентов для перорального применения
EP3062782A1 (en) 2013-10-30 2016-09-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
KR20160111013A (ko) 2014-02-11 2016-09-23 파넥스트 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합
US9700036B1 (en) 2015-04-08 2017-07-11 Justin P. Chatelain Duck decoy device
US9700037B1 (en) 2014-09-08 2017-07-11 Justin P. Chatelain Duck decoy device

Also Published As

Publication number Publication date
JP2017505786A (ja) 2017-02-23
US10905672B2 (en) 2021-02-02
WO2015121218A1 (en) 2015-08-20
EA201691602A1 (ru) 2017-03-31
EP3104850A1 (en) 2016-12-21
IL246856A0 (en) 2016-08-31
MX2016010409A (es) 2016-11-30
AU2015217796B2 (en) 2020-04-30
KR20160111013A (ko) 2016-09-23
US20160354335A1 (en) 2016-12-08
CA2938361A1 (en) 2015-08-20
JP6619744B2 (ja) 2019-12-11
AU2015217796A1 (en) 2016-08-18
CN106456583B (zh) 2020-04-07
CN106456583A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL288712A (en) Methods for treating abnormal movement disorders
IL246856A0 (en) A combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
IL255185A0 (en) 1-Heteroaryl-indoline-4-carboxamides as gpr52 modulators for treatment or prevention of related disorders
HK1252996A1 (zh) 用於治療癲癇的方法
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
HK1250624A1 (zh) 用於治療心血管障礙的方法
ZA201700037B (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions
SG11201706952VA (en) Compositions and methods for the treatment of epilepsy and neurological disorders
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201521542D0 (en) Methods for the treatment of cardiovascular disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders
GB201506419D0 (en) Methods for the treatment of inflammatory disorders
GB201506229D0 (en) Methods For the Treatment Of Inflammatory Disorders
GB201513991D0 (en) Methods for the treatment of cardiovascular disorders
GB201513344D0 (en) Methods for the treatment of Cardiovascular disorders
GB201507109D0 (en) Methods for the treatment of cardiovascular disorders
AU2014902257A0 (en) Treatment of immune disorders 2
GB201413533D0 (en) Combination therapy for treating disorders of the vestibular system